市場調査レポート
商品コード
1467881
自己幹細胞と非幹細胞ベースの治療市場レポート:タイプ、用途、エンドユーザー、地域別、2024~2032年Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report by Type, Application, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
自己幹細胞と非幹細胞ベースの治療市場レポート:タイプ、用途、エンドユーザー、地域別、2024~2032年 |
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
世界の自己幹細胞と非幹細胞ベースの治療市場規模は、2023年に77億米ドルに達しました。IMARC Groupは、2024~2032年にかけての成長率(CAGR)は11.87%で、2032年には216億米ドルに達すると予測しています。生命を脅かす疾患の増加、高齢者人口の増加、幹細胞技術の進歩は、市場を牽引する重要な要因のひとつです。
自己幹細胞ベースの治療は、患者の幹細胞を用いて損傷した組織や臓器を修復したり、様々な疾患を治療したりする医療行為です。この治療法では、患者の体内から幹細胞を採取し、通常は骨髄や脂肪組織から採取した幹細胞を加工して体内に戻します。一方、非幹細胞を用いた治療法は、幹細胞ではない細胞、例えば免疫細胞、線維芽細胞、筋肉細胞などを用いて、損傷した組織や臓器を修復・再生するものです。自己幹細胞ベースの治療は、心血管疾患、神経変性疾患、自己免疫疾患の治療に用いられ、非幹細胞ベースの治療は、慢性創傷、心臓病、パーキンソン病の治療に用いられています。
自己幹細胞と非幹細胞ベースの治療の世界市場の成長は、主に消費者の喫煙、食生活の乱れ、座りっぱなしのライフスタイルによる、がん、糖尿病、心血管障害、神経変性疾患の有病率の増加が牽引しています。これに加えて、高齢者人口の増加と自己幹細胞と非幹細胞ベースの治療に対する需要の高まりが、市場に明るい展望をもたらしています。さらに、再生医療を目指した革新的な自己幹細胞ベースの治療の市場開拓が進んでおり、個別化治療への需要が広がっていることも、市場に有益な成長機会をもたらしています。これに加えて、低侵襲治療の人気の高まり、幹細胞ベースの治療の受容の拡大、幹細胞研究に対する財政的・規制的支援のような政府の好意的なイニシアチブの実施が、市場の拡大を後押ししています。さらに、幹細胞技術の絶え間ない進歩により、研究開発者は幹細胞の分化をよりうまくコントロールできるようになり、より改善された効果的な治療法を開発できるようになりました。この他にも、医療セグメントの成長促進、広範な研究開発活動、消費者の健康意識の高まり、有利な償還政策などが市場成長に寄与しています。
The global autologous stem cell and non-stem cell based therapies market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.6 Billion by 2032, exhibiting a growth rate (CAGR) of 11.87% during 2024-2032. The increasing prevalence of life-threatening diseases, the expanding geriatric population, and ongoing advancements in stem cell technologies represent some of the key factors driving the market.
Autologous stem cell therapy is a medical procedure in which a patient's stem cells are used to repair damaged tissues and organs or treat various diseases. The procedure involves harvesting stem cells from a patient's body, usually from bone marrow or adipose tissue, and then processing and injecting them back into the body. Non-stem cell-based therapies, on the other hand, involve using cells that are not stem cells, such as immune cells, fibroblasts, and muscle cells, to repair or regenerate damaged tissues or organs. Autologous stem cell therapy is used to treat cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders, while non-stem cell-based therapies are employed in treating chronic wounds, heart disease, and Parkinson's disease.
The growth of the global autologous stem cell and non-stem cell based therapies market is primarily driven by the increasing prevalence of cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases due to smoking, poor diet, and sedentary lifestyles of consumers. Besides this, the rising geriatric population and the growing demand for autologous stem and non-stem cell based therapies are creating a positive outlook for the market. Moreover, the ongoing development of innovative autologous stem cell therapies for regenerative medicine and the widespread demand for personalized therapies are presenting remunerative growth opportunities for the market. In addition to this, the surging popularity of minimally invasive treatments, the expanding acceptance of stem cell therapies, and the implementation of favorable government initiatives, such as financial and regulatory support for stem cell research, are aiding in market expansion. Furthermore, continuous advancements in stem cell technologies have enabled researchers to better control the differentiation of stem cells and develop improved and effective treatments, which, in turn, is acting as a significant growth-inducing factor. Besides this, the bolstering growth of the healthcare sector, extensive research and development (R&D) activities, the escalating health consciousness among consumers, and favorable reimbursement policies are contributing to the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global autologous stem cell and non-stem cell based therapies market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, application, and end user.
Autologous Stem Cells
Autologous Non-Stem Cells
The report has provided a detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the type. This includes autologous stem cells and autologous non-stem cells. According to the report, autologous stem cells represented the largest segment.
Cancer
Neurodegenerative Disorders
Cardiovascular Disease
Orthopedic Diseases
Others
A detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the application has also been provided in the report. This includes cancer, neurodegenerative disorders, cardiovascular disease, orthopedic diseases, and others. According to the report, cancer accounted for the largest market share.
Hospitals
Ambulatory Surgical Centers
Research Facilities
The report has provided a detailed breakup and analysis of the autologous stem cell and non-stem cell based therapies market based on the end user. This includes hospitals, ambulatory surgical centers, and research facilities. According to the report, hospitals represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for autologous stem cell and non-stem cell based therapies. Some of the factors driving the North America autologous stem cell and non-stem cell based therapies market included the expanding prevalence of chronic diseases, the rising demand for personalized medicines, and continuous advancements in stem cell technologies.
The report has also provided a comprehensive analysis of the competitive landscape in the global autologous stem cell and non-stem cell based therapies market. Detailed profiles of all major companies have also been provided. Some of the companies covered include BrainStorm Cell Limited, Cytori Therapeutics Inc., Holostem Terapie Avanzate S.r.l., Lisata Therapeutics, U.S. Stem Cell Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.